EDMONTON, April 17 /CNW/ - (TSX:ISA) - Isotechnika Inc. announced today that The Lancet will publish an article titled “Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study” in this week’s edition of the publication. The article discusses the relationship between drug dose and clinical response demonstrated in the Canadian Phase 3 trial, suggesting that patients can be more accurately dosed to achieve desired response compared with currently marketed calcineurin inhibitors. An editorial will also be included on the use of voclosporin (ISA247) as a treatment for patients suffering from moderate to severe psoriasis.
